for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Eiger Biopharmaceuticals Inc

EIGR.OQ

Latest Trade

11.58USD

Change

-0.03(-0.26%)

Volume

104,569

Today's Range

11.53

 - 

11.82

52 Week Range

8.51

 - 

15.30

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
11.61
Open
11.60
Volume
104,569
3M AVG Volume
3.95
Today's High
11.82
Today's Low
11.53
52 Week High
15.30
52 Week Low
8.51
Shares Out (MIL)
24.45
Market Cap (MIL)
283.82
Forward P/E
-4.34
Dividend (Yield %)
--

Next Event

Eiger BioPharmaceuticals Inc at Ladenburg Thalmann Healthcare Conference

Latest Developments

More

Eiger Announces FDA Therapy For Peginterferon Lambda For Treatment Of Hepatitis Delta Virus Infection

Eiger BioPharmaceuticals Reports Q2 Loss Per Share $0.75

Eiger Announces Breakthrough Therapy Designation Granted By FDA For Avexitide

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Eiger Biopharmaceuticals Inc

Eiger BioPharmaceuticals, Inc., formerly Celladon Corporation, is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of products for the treatment of orphan diseases. Its pipeline includes Sarasar (lonafarnib) for hepatitis delta virus (HDV), exendin (9-39) for severe hypoglycemia, and Bestatin (ubenimex) for pulmonary arterial hypertension (PAH) and lymphedema. Lonafarnib is an orally active inhibitor of farnesyl transferase that inhibits the prenylation step of HDV replication inside liver cells and blocks the ability of the virus to multiply. It is conducting over three Phase II clinical trials, which include LOnafarnib With and without Ritonavir (LOWR) HDV-2 (Ankara, Turkey), LOWR HDV-3 (NIH) and LOWR HDV-4 (Hannover, Germany). Exendin is in Phase II clinical studies for the treatment of hypoglycemia associated with bariatric surgery. Ubenimex is in Phase II clinical studies for the treatment of PAH and lymphedema.

Industry

Biotechnology & Drugs

Contact Info

2155 Park Blvd

+1.650.2799845

http://www.eigerbio.com/

Executive Leadership

David A Cory

President, Chief Executive Officer, Director

Sriram Ryali

Chief Financial Officer

Stephana Eilene Patton

Chief Compliance Officer, General Counsel, Secretary

Rebecque J. Laba

Vice President - Corporate Operations

Jeffrey J. Rudy

Vice President - Clinical Operations

Key Stats

1.00 mean rating - 6 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2016

0.0K

2017

0.0K

2018

0.0K

2019(E)

0.0K
EPS (USD)

2016

-7.840

2017

-4.860

2018

-3.820

2019(E)

-2.678
Price To Earnings (TTM)
--
Price To Sales (TTM)
--
Price To Book (MRQ)
3.22
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
34.08
LT Debt To Equity (MRQ)
34.08
Return on Investment (TTM)
-73.46
Return on Equity (TTM)
-65.65

Latest News

BRIEF-Eiger Biopharmaceuticals Announces Proposed Public Offering Of Common Stock

* EIGER BIOPHARMACEUTICALS ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK

BRIEF-Progeria Research Foundation Announces Collaboration, Supply Agreement With Eiger Biopharma

* PROGERIA RESEARCH FOUNDATION ANNOUNCES COLLABORATION AND SUPPLY AGREEMENT WITH EIGER BIOPHARMACEUTICALS Source text for Eikon: Further company coverage:

BRIEF-Eiger Announces Expanded License Agreement With Merck For Lonafarnib

* EIGER ANNOUNCES EXPANDED LICENSE AGREEMENT WITH MERCK FOR INVESTIGATIONAL CANDIDATE LONAFARNIB AND COLLABORATION WITH THE PROGERIA RESEARCH FOUNDATION (PRF) Source text for Eikon: Further company coverage:

BRIEF-Eiger Biopharmaceuticals Reports First Quarter 2018 Financial Results

* EIGER BIOPHARMACEUTICALS REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS

BRIEF-Eiger Biopharmaceuticals Sees Phase 3 D-Livr Trial Starting In Second Half 2018​

* EIGER BIOPHARMACEUTICALS ANNOUNCES POSITIVE GUIDANCE FOLLOWING FDA MEETING ON HEPATITIS DELTA VIRUS REGISTRATION PROGRAM

BRIEF-Eiger Biopharmaceuticals Q4 Loss Per Share $1.11

* EIGER BIOPHARMACEUTICALS REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS

Eiger to abandon blood pressure drug after trial failure

Eiger BioPharmaceuticals Inc said on Tuesday it would stop development of its blood pressure drug after it failed in a mid-stage study, sending its shares plunging about 46 percent.

Eiger BioPharma abandons blood pressure drug after failed study

Eiger BioPharmaceuticals Inc said on Tuesday it would stop testing its drug ubenimex for the treatment of pulmonary arterial hypertension, a type of high blood pressure, after the drug failed to meet the main goal in a mid-stage study.

BRIEF-Eiger Biopharma Says Phase 2 Liberty Study In Pulmonary Arterial Hypertension Did Not Meet Main Goal

* EIGER BIOPHARMACEUTICALS ANNOUNCES PHASE 2 LIBERTY STUDY IN PULMONARY ARTERIAL HYPERTENSION DID NOT MEET PRIMARY ENDPOINT

BRIEF-Eiger Biopharma Files For Mixed Shelf Of Up To $125 Mln

* EIGER BIOPHARMACEUTICALS INC FILES FOR MIXED SHELF OF UP TO $125 MILLION - SEC FILING Source text: (http://bit.ly/2nUkpvR) Further company coverage:

BRIEF-‍Prosight Management reports a 6.9 percent passive stake in Eiger Biopharmaceuticals​

* Prosight Management reports a 6.9 percent passive stake in Eiger Biopharmaceuticals as of Oct 31 - SEC filing Source text: (http://bit.ly/2mbmToK) Further company coverage:

BRIEF-Eiger Biopharmaceuticals reports Q3 loss per share $1.10

* Eiger Biopharmaceuticals reports third quarter 2017 financial results

BRIEF-Eiger Biopharmaceuticals closes public offering

* Eiger Biopharmaceuticals announces closing of public offering of common stock and exercise in full of underwriter's option to purchase additional shares Source text for Eikon: Further company coverage:

BRIEF-EIGER BIOPHARMACEUTICALS ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK

* EIGER BIOPHARMACEUTICALS ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK

BRIEF-Eiger BioPharmaceuticals announces proposed public offering of common stock

* Eiger BioPharmaceuticals announces proposed public offering of common stock

BRIEF-Eiger appoints Evan Loh to its Board of Directors

* Eiger announces appointment of biopharmaceutical industry veteran Evan Loh, MD to its Board of Directors Source text for Eikon: Further company coverage:

BRIEF-Sphera Funds Management reports 5.35 pct passive stake in Eiger Biopharmaceuticals

* Sphera Funds Management Ltd reports a 5.35 percent passive stake in Eiger Biopharmaceuticals Inc as of August 17, 2017 - SEC Filing Source text: (http://bit.ly/2wBB2yX) Further company coverage:

BRIEF-Eiger Biopharmaceuticals Q2 loss per share $1.33

* Eiger Biopharmaceuticals reports second quarter 2017 financial results

BRIEF-Eiger announces FDA fast track designation granted for pegylated interferon lambda

* Eiger announces fda fast track designation granted for pegylated interferon lambda in hepatitis delta virus infection Source text for Eikon: Further company coverage:

BRIEF-Eiger BioPharma announces sale of non-strategic assets to Theragene Pharma

* Eiger BioPharmaceuticals announces sale of non-strategic assets to Theragene Pharmaceuticals

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up